OBJECTIVE To determine whether interferon therapy during human pregnancy increases reproductive risks in women. METHODS This longitudinal, controlled cohort study consisted of three groups of women: an exposed group, a disease matched unexposed group, and a healthy comparative group. Subjects were selected from women contacting the Motherisk Program regarding maternal beta interferon exposure...

Interferon (IFN) production by human peripheral lymphocytes stimulated with M. pneumoniae was investigated. The hydrogen peroxide released from M. pneumoniae was responsible for the induction of IFN from lymphocytes, since horseradish peroxidase inhibited the IFN production and abrogated the activity of IFN production in the supernatant of M. pneumoniae. The antiserum neutralizing IFN alpha and...

The viral genotype may influence the response to interferon (IFN) treatment in chronic hepatitis C virus (HCV) infection. To characterize potential mechanisms responsible for this effect, we assessed whether IFN modulation of HCV-specific T-cell responses differs in patients infected by different genotypes. The T-cell response to HCV core protein was sequentially analyzed before and during IFN ...

We report a patient with multiple sclerosis (MS) who developed subcutaneous nodules in the face, shoulders and extremities while being treated with interferon (IFN)-β-1b. These nodules fluctuated in parallel with myelopathy, and were diagnosed as lupus erythematosus profundus (LEP) based on histopathological findings. The patient showed no relapse of either neurological symptoms or subcutaneous...

Pure human beta interferon (Hu IFN-beta) (formerly human fibroblast interferon) was used to raise antibodies in rabbits. Anti-IFN-beta immunoglobulins from rabbit serum were purified by IFN-beta affinity chromatography and were used in the development of a sandwich-type radioimmunoassay for Hu IFN-beta. This radioimmunoassay consisted of (i) incubating Hu IFN-beta with anti-IFN-beta immunoglobu...

Beta interferon − INF 1b: Betaferon® and Extavia® (vial 250 g) INF 1a: Avonex® (vial 30 g); Rebif® (vial 22–44 g). Both also in syringes and preloaded containers. RR MS Pseudo-fever syndrome, depression, psychiatric disorders, moderate myelosuppression, hypotension, high liver enzymes, cough, dyspnea, proteinuria, OHT, hyperuricemia, KI, neuropathy, confusion, edema, hair loss, digestive altera...

OBJECTIVES To explore long-term effects of treatment and prognostic relevance of variables assessed at baseline and during the European secondary progressive multiple sclerosis (SPMS) trial of interferon beta 1b (IFNB-1b). METHODS We assessed 362 patients (60% female; median age 41 years; Expanded Disability Status Scale (EDSS): 5.5; 51% randomized to IFNB-1b) for their EDSS and treatment his...

The t(12;21) translocation is present in up to 30% of childhood B-cell acute lymphoblastic and fuses a potential dimerization motif from the ets-related factor TEL to the N terminus of AML1. The t(12;21) translocation encodes a 93-kDa fusion protein that localizes to a high-salt- and detergent-resistant nuclear compartment. This protein binds the enhancer core motif, TGTGGT, and interacts with ...

1aforearlymultiplesclerosis:CHAMPStrialsubgroup analyses. Ann Neurol. 2002;51:481-490. 42. Hadjimichael O, Vollmer TL. Adherence to injection therapy in multiple sclerosis: patients survey. Neurology. 1999;52:A549. 43. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interfer...

BACKGROUND All established disease-modifying drugs for multiple sclerosis require parenteral administration, which can cause difficulties for some patients, sometimes leading to suboptimal adherence. A new electronic autoinjection device has been designed to address these issues. METHODS Patients with relapsing multiple sclerosis currently receiving subcutaneous or intramuscular interferon be...